REGN vs RLI · P/E 14, rev $4.29B vs P/E 24, rev $999.4M
Regeneron Pharmaceuticals Inc (REGN) versus RLI Corp (RLI) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
RLI Corp (RLI) is a insurance - property & casualty company listed on US.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported RLI revenue for 2026-06-30 was $999.4M. Net income was $222.9M. RLI currently screens at market cap $6.58B and trailing P/E 23.7.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RLI currently screens at market cap $6.58B and trailing P/E 23.7.
Not investment advice. Open the REGN and RLI stock pages for the full models.
Not investment advice.